Pfizer (PFE) Stock Forecast, Price Target & Predictions
PFE Stock Forecast
Pfizer stock forecast is as follows: an average price target of $44.76 (represents a 59.34% upside from PFE’s last price of $28.09) and a rating consensus of 'Hold', based on 21 wall street analysts offering a 1-year stock forecast.
PFE Price Target
The average price target for Pfizer (PFE) is $44.76 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $20.00. This represents a potential 59.34% upside from PFE's last price of $28.09.
PFE Analyst Ratings
According to 21 Wall Street analysts, Pfizer's rating consensus is 'Hold'. The analyst rating breakdown for PFE stock is 1 'Strong Buy' (4.76%), 8 'Buy' (38.10%), 11 'Hold' (52.38%), 1 'Sell' (4.76%), and 0 'Strong Sell' (0.00%).
Pfizer Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | Chris Shibutani | Goldman Sachs | $33.00 | $28.46 | 15.95% | 17.48% |
| Oct 17, 2024 | Courtney Breen | Bernstein | $32.00 | $29.67 | 7.85% | 13.92% |
| Sep 25, 2024 | Carter Gould | Barclays | $32.00 | $28.93 | 10.61% | 13.92% |
| Aug 07, 2024 | Narumi Nakagiri | Daiwa | $34.00 | $28.85 | 17.85% | 21.04% |
| Jul 31, 2024 | Mohit Bansal | Wells Fargo | $30.00 | $31.39 | -4.43% | 6.80% |
| Jul 31, 2024 | Chris Shibutani | Goldman Sachs | $34.00 | $31.39 | 8.31% | 21.04% |
| Jul 30, 2024 | Vamil Divan | Guggenheim | $36.00 | $30.72 | 17.19% | 28.16% |
| Jul 10, 2024 | Carter Gould | Barclays | $30.00 | $27.72 | 8.23% | 6.80% |
| May 22, 2024 | Evan Seigerman | BMO Capital | $36.00 | $29.60 | 21.62% | 28.16% |
| Feb 14, 2024 | Louise Chen | Cantor Fitzgerald | $45.00 | $26.97 | 66.85% | 60.20% |
The latest Pfizer stock forecast, released on Oct 30, 2024 by Chris Shibutani from Goldman Sachs, set a price target of $33.00, which represents a 15.95% increase from the stock price at the time of the forecast ($28.46), and a 17.48% increase from PFE last price ($28.09).
Pfizer Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 4 | 12 |
| Avg Price Target | $32.50 | $32.75 | $33.25 |
| Last Closing Price | $28.09 | $28.09 | $28.09 |
| Upside/Downside | 15.70% | 16.59% | 18.37% |
In the current month, the average price target of Pfizer stock is $32.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 15.70% increase as opposed to Pfizer's last price of $28.09. This month's average price target is down -0.76% compared to last quarter, and down -2.26% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Oct 23, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Oct 17, 2024 | Bernstein | - | Market Perform | Initialise |
| Sep 25, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Sep 20, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Sep 20, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Sep 13, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jul 31, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Jul 31, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 31, 2024 | Goldman Sachs | Buy | Buy | Hold |
Pfizer's last stock rating was published by Goldman Sachs on Oct 30, 2024. The company gave PFE a "Buy" rating, the same as its previous rate.
Pfizer Financial Forecast
Pfizer Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $13.23B | $12.73B | $18.28B | $24.29B | $22.64B | $27.74B | $25.66B | $23.64B | $24.09B | $18.98B | $14.58B | $5.95B | $12.13B | $11.80B | $12.03B | $12.69B | $12.68B | $13.26B | $13.12B | $12.91B | $12.78B |
| Avg Forecast | $20.50B | $15.49B | $14.32B | $14.76B | $17.54B | $14.92B | $12.96B | $13.87B | $14.37B | $13.34B | $13.36B | $16.61B | $24.38B | $21.07B | $25.49B | $24.10B | $24.16B | $22.58B | $18.71B | $13.65B | $11.67B | $12.31B | $11.54B | $11.81B | $12.61B | $12.26B | $13.40B | $12.99B | $12.57B | $12.41B |
| High Forecast | $20.99B | $15.86B | $14.66B | $15.11B | $18.16B | $14.93B | $12.96B | $13.87B | $14.77B | $14.85B | $13.68B | $17.00B | $24.96B | $21.07B | $25.49B | $24.10B | $24.16B | $22.58B | $18.71B | $13.65B | $11.67B | $12.31B | $11.54B | $11.81B | $12.61B | $12.26B | $13.40B | $12.99B | $15.08B | $14.89B |
| Low Forecast | $19.51B | $14.74B | $13.63B | $14.04B | $16.80B | $14.91B | $12.96B | $13.87B | $14.13B | $12.24B | $12.72B | $15.80B | $23.20B | $21.07B | $25.49B | $24.10B | $24.16B | $22.58B | $18.71B | $13.65B | $11.67B | $12.31B | $11.54B | $11.81B | $12.61B | $12.26B | $13.40B | $12.99B | $10.06B | $9.93B |
| # Analysts | 1 | 1 | 1 | 1 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 0.95% | 1.10% | 1.00% | 1.07% | 1.09% | 1.06% | 0.98% | 1.07% | 1.01% | 1.07% | 0.51% | 0.99% | 1.02% | 1.02% | 1.01% | 1.03% | 0.99% | 1.01% | 1.03% | 1.03% |
Pfizer's average Quarter revenue forecast for Dec 23 based on 6 analysts is $14.37B, with a low forecast of $14.13B, and a high forecast of $14.77B. PFE's average Quarter revenue forecast represents a 8.59% increase compared to the company's last Quarter revenue of $13.23B (Sep 23).
Pfizer EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-803.00M | $4.21B | $8.40B | $7.56B | $11.25B | $13.31B | $11.52B | $5.32B | $9.50B | $8.25B | $7.24B | $1.42B | $3.85B | $5.57B | $5.48B | $282.00M | $12.69B | $6.05B | $6.22B | $5.99B | $5.81B |
| Avg Forecast | $6.90B | $5.21B | $4.82B | $4.97B | $5.90B | $5.02B | $4.36B | $7.96B | $4.84B | $4.49B | $4.50B | $8.52B | $3.63B | $7.09B | $8.58B | $9.11B | $8.13B | $7.60B | $6.30B | $5.74B | $3.93B | $4.14B | $3.89B | $4.96B | $4.24B | $4.13B | $4.51B | $5.39B | $5.83B | $5.63B |
| High Forecast | $7.07B | $5.34B | $4.94B | $5.09B | $6.11B | $5.03B | $4.36B | $9.56B | $4.97B | $5.00B | $4.60B | $10.22B | $4.35B | $7.09B | $8.58B | $10.93B | $8.13B | $7.60B | $6.30B | $6.89B | $3.93B | $4.14B | $3.89B | $5.95B | $4.24B | $4.13B | $4.51B | $6.47B | $7.00B | $6.76B |
| Low Forecast | $6.57B | $4.96B | $4.59B | $4.73B | $5.65B | $5.02B | $4.36B | $6.37B | $4.76B | $4.12B | $4.28B | $6.81B | $2.90B | $7.09B | $8.58B | $7.29B | $8.13B | $7.60B | $6.30B | $4.59B | $3.93B | $4.14B | $3.89B | $3.97B | $4.24B | $4.13B | $4.51B | $4.31B | $4.67B | $4.51B |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.18% | 0.94% | 0.99% | 2.08% | 1.59% | 1.55% | 1.26% | 0.65% | 1.25% | 1.31% | 1.26% | 0.36% | 0.93% | 1.43% | 1.11% | 0.07% | 3.07% | 1.34% | 1.15% | 1.03% | 1.03% |
10 analysts predict PFE's average Quarter EBITDA for Sep 23 to be $4.49B, with a high of $5.00B and a low of $4.12B. This is 6.66% upper than Pfizer's previous annual EBITDA (Jun 23) of $4.21B.
Pfizer Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | $-2.38B | $2.33B | $5.54B | $5.00B | $8.61B | $9.91B | $7.86B | $3.85B | $8.15B | $5.56B | $4.88B | $594.00M | $2.19B | $3.43B | $3.40B | $-336.00M | $7.68B | $5.05B | $3.88B | $3.56B | $3.12B |
| Avg Forecast | $6.21B | $3.78B | $3.37B | $4.28B | $2.76B | $3.51B | $2.61B | $5.94B | $-902.76M | $-455.48M | $3.25B | $6.35B | $2.31B | $7.90B | $9.82B | $6.79B | $4.98B | $6.13B | $5.53B | $3.86B | $2.87B | $4.07B | $3.85B | $3.07B | $3.28B | $3.52B | $4.29B | $3.37B | $3.47B | $3.03B |
| High Forecast | $6.40B | $3.90B | $3.47B | $4.41B | $3.39B | $3.58B | $2.61B | $7.13B | $-475.14M | $-313.14M | $3.35B | $7.62B | $2.78B | $8.23B | $9.82B | $8.15B | $4.98B | $6.13B | $5.64B | $4.64B | $2.87B | $4.07B | $3.85B | $3.69B | $3.28B | $3.52B | $4.29B | $4.04B | $4.16B | $3.63B |
| Low Forecast | $5.82B | $3.54B | $3.16B | $4.01B | $2.03B | $3.43B | $2.61B | $4.75B | $-1.33B | $-683.23M | $3.05B | $5.08B | $1.85B | $7.57B | $9.82B | $5.44B | $4.98B | $6.13B | $5.41B | $3.09B | $2.87B | $4.07B | $3.85B | $2.46B | $3.28B | $3.52B | $4.29B | $2.69B | $2.77B | $2.42B |
| Surprise % | - | - | - | - | - | - | - | - | - | 5.23% | 0.72% | 0.87% | 2.16% | 1.09% | 1.01% | 1.16% | 0.77% | 1.33% | 1.01% | 1.26% | 0.21% | 0.54% | 0.89% | 1.11% | -0.10% | 2.18% | 1.18% | 1.15% | 1.03% | 1.03% |
Pfizer's average Quarter net income forecast for Sep 23 is $-455.48M, with a range of $-683.23M to $-313.14M. PFE's average Quarter net income forecast represents a -119.57% decrease compared to the company's last Quarter net income of $2.33B (Jun 23).
Pfizer SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | $3.28B | $3.50B | $3.42B | $4.64B | $3.39B | $3.05B | $2.59B | $4.09B | $2.90B | $2.93B | $2.78B | $2.70B | $3.02B | $2.81B | $2.74B | $4.24B | $3.26B | $3.51B | $3.34B | $3.41B | $3.31B |
| Avg Forecast | $4.49B | $3.39B | $3.13B | $3.23B | $3.84B | $3.27B | $2.84B | $1.96B | $3.15B | $2.92B | $2.92B | $2.09B | $2.79B | $4.61B | $5.58B | $2.24B | $5.29B | $4.94B | $4.09B | $2.20B | $2.55B | $2.69B | $2.53B | $2.48B | $2.76B | $2.68B | $2.93B | $2.89B | $3.32B | $3.21B |
| High Forecast | $4.59B | $3.47B | $3.21B | $3.31B | $3.98B | $3.27B | $2.84B | $2.35B | $3.23B | $3.25B | $2.99B | $2.51B | $3.34B | $4.61B | $5.58B | $2.69B | $5.29B | $4.94B | $4.09B | $2.65B | $2.55B | $2.69B | $2.53B | $2.98B | $2.76B | $2.68B | $2.93B | $3.47B | $3.99B | $3.85B |
| Low Forecast | $4.27B | $3.23B | $2.98B | $3.07B | $3.68B | $3.26B | $2.84B | $1.57B | $3.09B | $2.68B | $2.78B | $1.68B | $2.23B | $4.61B | $5.58B | $1.79B | $5.29B | $4.94B | $4.09B | $1.76B | $2.55B | $2.69B | $2.53B | $1.98B | $2.76B | $2.68B | $2.93B | $2.32B | $2.66B | $2.57B |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.12% | 1.20% | 1.63% | 1.67% | 0.74% | 0.55% | 1.16% | 0.77% | 0.59% | 0.72% | 1.26% | 1.06% | 1.12% | 1.11% | 1.11% | 1.54% | 1.21% | 1.20% | 1.15% | 1.03% | 1.03% |
Pfizer's average Quarter SG&A projection for Dec 23 is $3.15B, based on 6 Wall Street analysts, with a range of $3.09B to $3.23B. The forecast indicates a -4.14% fall compared to PFE last annual SG&A of $3.28B (Sep 23).
Pfizer EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.42 | $0.41 | $0.98 | $0.89 | $1.54 | $1.77 | $1.40 | $0.69 | $1.45 | $0.99 | $0.87 | $0.11 | $0.39 | $0.62 | $0.61 | $-0.06 | $1.38 | $0.91 | $0.69 | $0.60 | $0.52 |
| Avg Forecast | $1.09 | $0.66 | $0.59 | $0.75 | $0.48 | $0.61 | $0.46 | $0.52 | $-0.16 | $-0.08 | $0.57 | $0.98 | $1.05 | $1.39 | $1.72 | $1.49 | $0.87 | $1.08 | $0.97 | $0.78 | $0.50 | $0.71 | $0.68 | $0.73 | $0.58 | $0.62 | $0.75 | $0.75 | $0.73 | $0.65 |
| High Forecast | $1.12 | $0.68 | $0.61 | $0.77 | $0.59 | $0.63 | $0.46 | $0.52 | $-0.08 | $-0.05 | $0.59 | $1.01 | $1.08 | $1.45 | $1.72 | $1.53 | $0.87 | $1.08 | $0.99 | $0.78 | $0.50 | $0.71 | $0.68 | $0.73 | $0.58 | $0.62 | $0.75 | $0.75 | $0.88 | $0.78 |
| Low Forecast | $1.02 | $0.62 | $0.55 | $0.70 | $0.36 | $0.60 | $0.46 | $0.51 | $-0.23 | $-0.12 | $0.53 | $0.92 | $0.98 | $1.33 | $1.72 | $1.46 | $0.87 | $1.08 | $0.95 | $0.78 | $0.50 | $0.71 | $0.68 | $0.73 | $0.58 | $0.62 | $0.75 | $0.75 | $0.58 | $0.52 |
| Surprise % | - | - | - | - | - | - | - | - | - | 5.26% | 0.72% | 1.00% | 0.85% | 1.11% | 1.03% | 0.94% | 0.79% | 1.35% | 1.02% | 1.12% | 0.22% | 0.55% | 0.92% | 0.83% | -0.10% | 2.23% | 1.21% | 0.92% | 0.82% | 0.80% |
According to 10 Wall Street analysts, Pfizer's projected average Quarter EPS for Sep 23 is $-0.08, with a low estimate of $-0.12 and a high estimate of $-0.05. This represents a -119.47% decrease compared to PFE previous annual EPS of $0.41 (Jun 23).
Pfizer Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $28.09 | $44.76 | 59.34% | Hold |
| MRK | Merck | $101.88 | $129.47 | 27.08% | Buy |
| BMY | Bristol-Myers Squibb Company | $54.32 | $64.57 | 18.87% | Hold |
| JNJ | Johnson & Johnson | $160.13 | $179.13 | 11.87% | Buy |
| LLY | Eli Lilly and Company | $818.93 | $782.65 | -4.43% | Buy |
| AMGN | Amgen | $319.22 | $293.15 | -8.17% | Buy |
| GILD | Gilead Sciences | $89.51 | $81.32 | -9.15% | Buy |
| ABBV | AbbVie | $203.55 | $174.04 | -14.50% | Buy |
PFE Forecast FAQ
Is Pfizer a good buy?
No, according to 21 Wall Street analysts, Pfizer (PFE) is considered a 'Hold'. The rating consensus is based on 1 'Strong Buy' and 8 'Buy' recommendations, accounting for 42.86% of PFE's total ratings.
What is PFE's price target?
Pfizer (PFE) average price target is $44.76 with a range of $20 to $70, implying a 59.34% from its last price of $28.09. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Pfizer stock go up soon?
According to Wall Street analysts' prediction for PFE stock, the company can go up by 59.34% (from the last price of $28.09 to the average price target of $44.76), up by 149.20% based on the highest stock price target, and down by -28.80% based on the lowest stock price target.
Can Pfizer stock reach $40?
PFE's average twelve months analyst stock price target of $44.76 supports the claim that Pfizer can reach $40 in the near future.
What is Pfizer's current price target trend?
2 Wall Street analysts forecast a $32.5 price target for Pfizer (PFE) this month, up 15.70% from its last price of $28.09. Compared to the last 3 and 12 months, the average price target increased by 16.59% and increased by 18.37%, respectively.
What are Pfizer's analysts' financial forecasts?
Pfizer's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $59.29B (high $59.93B, low $58.54B), average EBITDA is $23.25B (high $25.06B, low $21.41B), average net income is $14.82B (high $16.71B, low $12.83B), average SG&A $11.9B (high $12.43B, low $11.34B), and average EPS is $2.07 (high $2.2, low $1.93). PFE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $65.07B (high $66.61B, low $61.93B), average EBITDA is $21.91B (high $22.42B, low $20.85B), average net income is $17.64B (high $18.18B, low $16.53B), average SG&A $14.24B (high $14.58B, low $13.55B), and average EPS is $3.09 (high $3.19, low $2.9).
Did the PFE's actual financial results beat the analysts' financial forecasts?
Based on Pfizer's last annual report (Dec 2022), the company's revenue was $100.33B, beating the average analysts forecast of $95.04B by 5.57%. Apple's EBITDA was $43.64B, beating the average prediction of $28.41B by 53.60%. The company's net income was $31.37B, beating the average estimation of $26.83B by 16.92%. Apple's SG&A was $13.68B, missing the average forecast of $15.22B by -10.13%. Lastly, the company's EPS was $5.59, missing the average prediction of $5.65 by -1.09%. In terms of the last quarterly report (Sep 2023), Pfizer's revenue was $13.23B, missing the average analysts' forecast of $13.34B by -0.81%. The company's EBITDA was $-803M, missing the average prediction of $4.49B by -117.88%. Pfizer's net income was $-2.382B, beating the average estimation of $-455M by 422.97%. The company's SG&A was $3.28B, beating the average forecast of $2.92B by 12.37%. Lastly, the company's EPS was $-0.42, beating the average prediction of $-0.0798 by 426.07%